Search Results

There are 2845 results for: content related to: Second primary melanomas on treatment with vemurafenib: reply from the authors

  1. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease

    British Journal of Dermatology

    Volume 171, Issue 6, December 2014, Pages: 1529–1532, C. Brugière, A. Stefan, C. Morice, E. Cornet, A. Moreau, S. Allouche and L. Verneuil

    Article first published online : 9 NOV 2014, DOI: 10.1111/bjd.13300

  2. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities

    British Journal of Dermatology

    Volume 167, Issue 5, November 2012, Pages: 987–994, R. Sinha, K. Edmonds, J.A. Newton-Bishop, M.E. Gore, J. Larkin and L. Fearfield

    Article first published online : 29 OCT 2012, DOI: 10.1111/bjd.12010

  3. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas

    British Journal of Dermatology

    Volume 169, Issue 4, October 2013, Pages: 934–938, E. Regnier-Rosencher, H. Lazareth, L. Gressier, M.F. Avril, E. Thervet and N. Dupin

    Article first published online : 10 OCT 2013, DOI: 10.1111/bjd.12555

  4. You have free access to this content
    The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S3, April 2014, Pages: 1–15, Michael P Brown and Georgina V Long

    Article first published online : 8 APR 2014, DOI: 10.1111/ajco.12200

  5. You have free access to this content
    Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks

    British Journal of Dermatology

    Volume 172, Issue 1, January 2015, Pages: 239–243, R. Anforth, G. Carlos, A. Clements, R. Kefford and P. Fernandez-Peñas

    Article first published online : 21 NOV 2014, DOI: 10.1111/bjd.13200

  6. You have full text access to this OnlineOpen article
    A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

    Pharmacology Research & Perspectives

    Volume 3, Issue 2, March 2015, Simone M. Goldinger, Jeannine Rinderknecht, Reinhard Dummer, Felix Pierre Kuhn, Kuo-Hsiung Yang, Lucy Lee, Ruben C. Ayala, Jagdish Racha, Wanping Geng, David Moore, Mei Liu, Andrew K. Joe, Selby Patricia Gil Bazan and Joseph F. Grippo

    Article first published online : 2 FEB 2015, DOI: 10.1002/prp2.113

  7. Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis

    British Journal of Dermatology

    Volume 172, Issue 5, May 2015, Pages: 1454–1455, G. Jeudy, S. Dalac-Rat, B. Bonniaud, A. Hervieu, T. Petrella, E. Collet and P. Vabres

    Article first published online : 15 MAR 2015, DOI: 10.1111/bjd.13522

  8. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process

    Journal of Pharmaceutical Sciences

    Volume 102, Issue 3, March 2013, Pages: 967–981, Navnit Shah, Raman M. Iyer, Hans-Juergen Mair, Duk Soon Choi, Hung Tian, Ralph Diodone, Karsten Fähnrich, Anni Pabst-Ravot, Kin Tang, Emmanuel Scheubel, Joseph F. Grippo, Sebastian A. Moreira, Zenaida Go, James Mouskountakis, Theresa Louie, Prabha N. Ibrahim, Harpreet Sandhu, Linda Rubia, Hitesh Chokshi, Dharmendra Singhal and Waseem Malick

    Article first published online : 29 DEC 2012, DOI: 10.1002/jps.23425

  9. Human papillomavirus evaluation of vemurafenib-induced skin epithelial tumors: a case series

    British Journal of Dermatology

    Volume 172, Issue 2, February 2015, Pages: 540–542, E. Dika, A. Patrizi, S. Venturoli, P.A. Fanti, D. Barbieri, R. Strammiello, B. Melotti and M. La Placa

    Article first published online : 16 DEC 2014, DOI: 10.1111/bjd.13275

  10. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors

    Pigment Cell & Melanoma Research

    Casey G. Langdon, Matthew A. Held, James T. Platt, Katrina Meeth, Pinar Iyidogan, Ramanaiah Mamillapalli, Andrew B. Koo, Michael Klein, Zongzhi Liu, Marcus W. Bosenberg and David F. Stern

    Article first published online : 6 MAY 2015, DOI: 10.1111/pcmr.12376

  11. You have full text access to this OnlineOpen article
    Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting

    Cancer Medicine

    Geoffrey T. Gibney, Geneviève Gauthier, Charles Ayas, Philip Galebach, Eric Q. Wu, Sarang Abhyankar, Carolina Reyes, Annie Guérin and Yeun Mi Yim

    Article first published online : 20 MAY 2015, DOI: 10.1002/cam4.475

  12. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption

    Journal of Cutaneous Pathology

    Volume 41, Issue 6, June 2014, Pages: 539–543, Inbal Braunstein, Tara C. Gangadhar, Rosalie Elenitsas and Emily Y. Chu

    Article first published online : 11 MAR 2014, DOI: 10.1111/cup.12318

  13. Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors

    British Journal of Dermatology

    E. Vigarios, L. Lamant, J.P. Delord, J.C. Fricain, C. Chevreau, B. Barrés, C. Gomez-Roca, M. Boulanger and V. Sibaud

    Article first published online : 19 APR 2015, DOI: 10.1111/bjd.13610

  14. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma

    British Journal of Dermatology

    Volume 170, Issue 1, January 2014, Pages: 220–222, A. Koop, I. Satzger, M. Alter, A. Kapp, A. Hauschild and R. Gutzmer

    Article first published online : 13 JAN 2014, DOI: 10.1111/bjd.12615

  15. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel

    British Journal of Dermatology

    Volume 168, Issue 4, April 2013, Pages: 700–707, D. Gonzalez, L. Fearfield, P. Nathan, P. Tanière, A. Wallace, E. Brown, C. Harwood, J. Marsden and S. Whittaker

    Article first published online : 25 MAR 2013, DOI: 10.1111/bjd.12248

  16. You have free access to this content
    Society for Melanoma Research 2014 Congress

    Pigment Cell & Melanoma Research

    Volume 27, Issue 6, November 2014, Pages: 1169–1241,

    Article first published online : 23 OCT 2014, DOI: 10.1111/pcmr.12317

  17. You have free access to this content
    Society for Melanoma Research 2013 Congress

    Pigment Cell & Melanoma Research

    Volume 26, Issue 6, November 2013, Pages: 932–1019,

    Article first published online : 24 OCT 2013, DOI: 10.1111/pcmr.12166

  18. You have free access to this content
    Society for Melanoma Research 2012 Congress

    Pigment Cell & Melanoma Research

    Volume 25, Issue 6, November 2012, Pages: 836–903,

    Article first published online : 19 OCT 2012, DOI: 10.1111/pcmr.12023

  19. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors

    British Journal of Dermatology

    Volume 169, Issue 6, December 2013, Pages: 1310–1313, R. Anforth, T.C.M.P. Blumetti, A. Clements, R. Kefford, G.V. Long and P. Fernandez-Peñas

    Article first published online : 2 DEC 2013, DOI: 10.1111/bjd.12519

  20. Second primary melanomas treated with BRAF blockers: study by reflectance confocal microscopy

    British Journal of Dermatology

    Volume 168, Issue 6, June 2013, Pages: 1230–1235, S. Debarbieux, S. Dalle, L. Depaepe, N. Poulalhon, B. Balme and L. Thomas

    Article first published online : 1 APR 2013, DOI: 10.1111/bjd.12210